Search

Your search keyword '"Martinez, Fernando J."' showing total 1,799 results
Start Over Author "Martinez, Fernando J." Language english
1,799 results on '"Martinez, Fernando J."'

4. Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts

Author

Adegunsoye, Ayodeji, Newton, Chad A., Oldham, Justin M., Ley, Brett, Lee, Cathryn T., Linderholm, Angela L., Chung, Jonathan H., Garcia, Nicole, Zhang, Da, Vij, Rekha, Guzy, Robert, Jablonski, Renea, Bag, Remzi, Voogt, Rebecca S., Ma, Shwu-Fan, Sperling, Anne I., Raghu, Ganesh, Martinez, Fernando J., Strek, Mary E., Wolters, Paul J., Garcia, Christine Kim, Pierce, Brandon L., and Noth, Imre

Published
2023
Full Text
View/download PDF

5. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

Author

Rahaghi, Franck F., Hsu, Vivien M., Kaner, Robert J., Mayes, Maureen D., Rosas, Ivan O., Saggar, Rajan, Steen, Virginia D., Strek, Mary E., Bernstein, Elana J., Bhatt, Nitin, Castelino, Flavia V., Chung, Lorinda, Domsic, Robyn T., Flaherty, Kevin R., Gupta, Nishant, Kahaleh, Bashar, Martinez, Fernando J., Morrow, Lee E., Moua, Teng, Patel, Nina, Shlobin, Oksana A., Southern, Brian D., Volkmann, Elizabeth R., and Khanna, Dinesh

Published
2023
Full Text
View/download PDF

6. A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD

Author

DiLillo, Katarina M., Norman, Katy C., Freeman, Christine M., Christenson, Stephanie A., Alexis, Neil E., Anderson, Wayne H., Barjaktarevic, Igor Z., Barr, R. Graham, Comellas, Alejandro P., Bleecker, Eugene R., Boucher, Richard C., Couper, David J., Criner, Gerard J., Doerschuk, Claire M., Wells, J. Michael, Han, MeiLan K., Hoffman, Eric A., Hansel, Nadia N., Hastie, Annette T., Kaner, Robert J., Krishnan, Jerry A., Labaki, Wassim W., Martinez, Fernando J., Meyers, Deborah A., O’Neal, Wanda K., Ortega, Victor E., Paine, III, Robert, Peters, Stephen P., Woodruff, Prescott G., Cooper, Christopher B., Bowler, Russell P., Curtis, Jeffrey L., and Arnold, Kelly B.

Published
2023
Full Text
View/download PDF

9. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

Author

Agustí, Alvar, Celli, Bartolome R., Criner, Gerard J., Halpin, David, Anzueto, Antonio, Barnes, Peter, Bourbeau, Jean, Han, MeiLan K., Martinez, Fernando J., Montes de Oca, Maria, Mortimer, Kevin, Papi, Alberto, Pavord, Ian, Roche, Nicolas, Salvi, Sundeep, Sin, Don D., Singh, Dave, Stockley, Robert, López Varela, M. Victorina, Wedzicha, Jadwiga A., and Vogelmeier, Claus F.

Published
2023
Full Text
View/download PDF

10. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD

Author

Alexis, Neil E., Anderson, Wayne H., Arjomandi, Mehrdad, Barjaktarevic, Igor, Barr, R. Graham, Basta, Patricia, Bateman, Lori A., Bhatt, Surya P., Bleecker, Eugene R., Boucher, Richard C., Bowler, Russell P., Christenson, Stephanie A., Comellas, Alejandro P., Cooper, Christopher B., Couper, David J., Criner, Gerard J., Crystal, Ronald G., Curtis, Jeffrey L., Doerschuk, Claire M., Dransfield, Mark T., Drummond, Brad, Freeman, Christine M., Galban, Craig, Han, MeiLan K., Hansel, Nadia N., Hastie, Annette T., Hoffman, Eric A., Huang, Yvonne, Kaner, Robert J., Kanner, Richard E., Kleerup, Eric C., Krishnan, Jerry A., LaVange, Lisa M., Lazarus, Stephen C., Martinez, Fernando J., Meyers, Deborah A., Moore, Wendy C., Newell, John D., Jr., Paine, Robert, III, Paulin, Laura, Peters, Stephen P., Pirozzi, Cheryl, Putcha, Nirupama, Oelsner, Elizabeth C., O’Neal, Wanda K., Ortega, Victor E., Raman, Sanjeev, Rennard, Stephen I., Tashkin, Donald P., Wells, J. Michael, Wise, Robert A., Woodruff, Prescott G., Fortis, Spyridon, Quibrera, Pedro M., Dransfield, Mark B., Dolezal, Brett A., Kim, Victor, Barjaktarevic, Igor Z., and Couper, David

Published
2023
Full Text
View/download PDF

11. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort

Author

LeMaster, W. Blake, Quibrera, P. Miguel, Couper, David, Tashkin, Donald P., Bleecker, Eugene R., Doerschuk, Claire M., Ortega, Victor E., Cooper, Christopher, Han, MeiLan K., Woodruff, Prescott G., O’Neal, Wanda K., Anderson, Wayne H., Alexis, Neil E., Bowler, Russell P., Barr, R. Graham, Kaner, Robert J., Dransfield, Mark T., Paine, Robert, III, Kim, Victor, Curtis, Jeffrey L., Martinez, Fernando J., Hastie, Annette T., and Barjaktarevic, Igor

Published
2023
Full Text
View/download PDF

13. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study

Author

Chaudhary, Muhammad F A, Hoffman, Eric A, Guo, Junfeng, Comellas, Alejandro P, Newell, John D, Jr, Nagpal, Prashant, Fortis, Spyridon, Christensen, Gary E, Gerard, Sarah E, Pan, Yue, Wang, Di, Abtin, Fereidoun, Barjaktarevic, Igor Z, Barr, R Graham, Bhatt, Surya P, Bodduluri, Sandeep, Cooper, Christopher B, Gravens-Mueller, Lisa, Han, MeiLan K, Kazerooni, Ella A, Martinez, Fernando J, Menchaca, Martha G, Ortega, Victor E, III, Robert Paine, Schroeder, Joyce D, Woodruff, Prescott G, and Reinhardt, Joseph M

Published
2023
Full Text
View/download PDF

14. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study

Author

Allen, Richard J, Oldham, Justin M, Jenkins, David A, Leavy, Olivia C, Guillen-Guio, Beatriz, Melbourne, Carl A, Ma, Shwu-Fan, Jou, Jonathan, Kim, John S, Fahy, William A, Oballa, Eunice, Hubbard, Richard B, Navaratnam, Vidya, Braybrooke, Rebecca, Saini, Gauri, Roach, Katy M, Tobin, Martin D, Hirani, Nik, Whyte, Moira K B, Kaminski, Naftali, Zhang, Yingze, Martinez, Fernando J, Linderholm, Angela L, Adegunsoye, Ayodeji, Strek, Mary E, Maher, Toby M, Molyneaux, Philip L, Flores, Carlos, Noth, Imre, Gisli Jenkins, R, and Wain, Louise V

Published
2023
Full Text
View/download PDF

15. Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts

Author

Choi, Bina, Adan, Najma, Doyle, Tracy J., San José Estépar, Ruben, Harmouche, Rola, Humphries, Stephen M., Moll, Matthew, Cho, Michael H., Putman, Rachel K., Hunninghake, Gary M., Kalhan, Ravi, Liu, Gabrielle Y., Diaz, Alejandro A., Mason, Stefanie E., Rahaghi, Farbod N., Pistenmaa, Carrie L., Enzer, Nicholas, Poynton, Clare, Sánchez-Ferrero, Gonzalo Vegas, Ross, James C., Lynch, David A., Martinez, Fernando J., Han, MeiLan K., Bowler, Russell P., Wilson, David O., Rosas, Ivan O., Washko, George R., San José Estépar, Raúl, and Ash, Samuel Y.

Published
2023
Full Text
View/download PDF

19. Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis

Author

Ghosh, Auyon J., Hobbs, Brian D., Yun, Jeong H., Saferali, Aabida, Moll, Matthew, Xu, Zhonghui, Chase, Robert P., Morrow, Jarrett, Ziniti, John, Sciurba, Frank, Barwick, Lucas, Limper, Andrew H., Flaherty, Kevin, Criner, Gerard, Brown, Kevin K., Wise, Robert, Martinez, Fernando J., McGoldrick, Daniel, Cho, Michael H., DeMeo, Dawn L., Silverman, Edwin K., Castaldi, Peter J., and Hersh, Craig P.

Published
2022
Full Text
View/download PDF

21. Black carbon content in airway macrophages is associated with increased severe exacerbations and worse COPD morbidity in SPIROMICS

Author

Tejwani, Vickram, Woo, Han, Liu, Chen, Tillery, Anna K., Gassett, Amanda J., Kanner, Richard E., Hoffman, Eric A., Martinez, Fernando J., Woodruff, Prescott G., Barr, R. Graham, Fawzy, Ashraf, Koehler, Kirsten, Curtis, Jeffrey L., Freeman, Christine M., Cooper, Christopher B., Comellas, Alejandro P., Pirozzi, Cheryl, Paine, Robert, Tashkin, Donald, Krishnan, Jerry A., Sack, Coralynn, Putcha, Nirupama, Paulin, Laura M., Zusman, Marina, Kaufman, Joel D., Alexis, Neil E., and Hansel, Nadia N.

Published
2022
Full Text
View/download PDF

24. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD

Author

Alexis, Neil E., Anderson, Wayne H., Arjomandi, Mehrdad, Barjaktarevic, Igor, Barr, R. Graham, Bateman, Lori A., Bhatt, Surya P., Bleecker, Eugene R., Boucher, Richard C., Bowler, Russell P., Christenson, Stephanie A., Comellas, Alejandro P., Cooper, Christopher B., Couper, David J., Criner, Gerard J., Crystal, Ronald G., Curtis, Jeffrey L., Doerschuk, Claire M., Dransfield, Mark T., Drummond, Brad, Freeman, Christine M., Galban, Craig, Han, MeiLan K., Hansel, Nadia N., Hastie, Annette T., Hoffman, Eric A., Huang, Yvonne, Kaner, Robert J., Kanner, Richard E., Kleerup, Eric C., Krishnan, Jerry A., LaVange, Lisa M., Lazarus, Stephen C., Martinez, Fernando J., Meyers, Deborah A., Moore, Wendy C., Newell, John D., Jr., Paine, Robert, III, Paulin, Laura, Peters, Stephen P., Pirozzi, Cheryl, Putcha, Nirupama, Oelsner, Elizabeth C., O’Neal, Wanda K., Ortega, Victor E., Raman, Sanjeev, Rennard, Stephen I., Tashkin, Donald P., Wells, J. Michael, Wise, Robert A., Woodruff, Prescott G., Esther, Charles R., Jr., Kesimer, Mehmet, Ceppe, Agathe, Tesfaigzi, Yohannes, Kim, Victor, Paulin, Laura M., Huang, Yvonne J., and Labaki, Wassim W.

Published
2022
Full Text
View/download PDF

25. Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort

Author

Yee, Nathan, Markovic, Daniela, Buhr, Russell G., Fortis, Spyridon, Arjomandi, Mehrdad, Couper, David, Anderson, Wayne H., Paine, Robert, III, Woodruff, Prescott G., Han, Meilan K., Martinez, Fernando J., Barr, R. Graham, Wells, James M., Ortega, Victor E., Hoffman, Eric A., Kim, Victor, Drummond, M. Bradley, Bowler, Russell P., Curtis, Jeffrey L., Cooper, Christopher B., Tashkin, Donald P., and Barjaktarevic, Igor Z.

Published
2022
Full Text
View/download PDF

26. AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.

Author

Rabe, Klaus F., Martinez, Fernando J., Bhatt, Surya P., Tomotaka Kawayama, Cosio, Borja G., Mroz, Robert M., Boomsma, Maarten M., Goulaouic, Helene, Nivens, Michael C., Djandji, Michel, Soler, Xavier, Ying Liu, Kosloski, Matthew P., Xu, Christine R., Amin, Nikhil, Staudinger, Heribert, Lederer, David J., and Abdulai, Raolat M.

Published
2024
Full Text
View/download PDF

27. Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis.

Author

Pugashetti, Janelle Vu, Kim, John S., Bose, Swaraj, Adegunsoye, Ayodeji, Linderholm, Angela L., Chen, Ching-Hsien, Strek, Mary E., Flaherty, Kevin R., Murray, Susan, Newton, Chad A., Alqalyoobi, Shehabaldin, Ma, Shwu-Fan, Mychaleckyj, Josyf C., Bowler, Russell P., Han, MeiLan K., Curtis, Jeffrey L., Martinez, Fernando J., Smith, Jennifer A., Noth, Imre, and Oldham, Justin M.

Subjects
AGE, PULMONARY fibrosis, IDIOPATHIC pulmonary fibrosis, CHRONIC obstructive pulmonary disease, INTERSTITIAL lung diseases
Abstract

Rationale: Accelerated biological aging has been implicated in the development of interstitial lung disease (ILD) and other diseases of aging but remains poorly understood. Objectives: To identify plasma proteins that mediate the relationship between chronological age and survival association in patients with ILD. Methods: Causal mediation analysis was performed to identify plasma proteins that mediated the chronological age–survival relationship in an idiopathic pulmonary fibrosis discovery cohort. Proteins mediating this relationship after adjustment for false discovery were advanced for testing in an independent ILD validation cohort and explored in a chronic obstructive pulmonary disease cohort. A proteomic-based measure of biological age was constructed and survival analysis performed, assessing the impact of biological age and peripheral blood telomere length on the chronological age–survival relationship. Measurements and Main Results: Twenty-two proteins mediated the chronological age–survival relationship after adjustment for false discovery in the idiopathic pulmonary fibrosis discovery cohort (n = 874), with 19 remaining significant mediators of this relationship in the ILD validation cohort (n = 983) and one mediating this relationship in the chronic obstructive pulmonary disease cohort. Latent transforming growth factor-β binding protein 2 and ectodysplasin A2 receptor showed the strongest mediation across cohorts. A proteomic measure of biological age completely attenuated the chronological age–survival association and better discriminated survival than chronological age. Results were robust to adjustment for peripheral blood telomere length, which did not mediate the chronological age–survival relationship. Conclusions: Molecular measures of aging completely mediate the relationship between chronological age and survival, suggesting that chronological age has no direct effect on ILD survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Air Pollution Exposure and Interstitial Lung Features in SPIROMICS Participants with Chronic Obstructive Pulmonary Disease.

Author

Baddour, Nicolas A., Paulin, Laura M., Gassett, Amanda J., Woo, Han, Hoffman, Eric A., Newell Jr., John D., Woodruff, Prescott G., Pirozzi, Cheryl S., Barjaktarevic, Igor, Barr, R. Graham, O'Neal, Wanda, Han, Meilan K., Martinez, Fernando J., Peters, Stephen P., Hastie, Annette T., Hansel, Nadia N., Ortega, Victor E., Kaufman, Joel D., and Sack, Coralynn S.

Subjects
LUNGS, AIR pollution, CHRONIC obstructive pulmonary disease, AIR pollutants, INTERSTITIAL lung diseases, GENOTYPE-environment interaction, PARTICULATE matter
Abstract

Rationale: It is unknown whether air pollution is associated with radiographic features of interstitial lung disease in individuals with chronic obstructive pulmonary disease (COPD). Objectives: To determine whether air pollution increases the prevalence of interstitial lung abnormalities (ILA) or percent high-attenuation areas (HAA) on computed tomography (CT) in individuals with a heavy smoking history and COPD. Methods: We performed a cross-sectional study of SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study), focused on current or former smokers with COPD. Ten-year exposure to particulate matter ⩽2.5 μm in aerodynamic diameter (PM2.5), nitrogen oxides (NOx), nitrogen dioxide (NO2), and ozone before enrollment CT (completed between 2010 and 2015) were estimated with validated spatiotemporal models at residential addresses. We applied adjusted multivariable modified Poisson regression and linear regression to investigate associations between pollution exposure and relative risk (RR) of ILA or increased percent HAA (between −600 and −250 Hounsfield units), respectively. We assessed for effect modification by MUC5B-promoter polymorphism (variant allele carriers GT or TT vs. GG at rs3705950), smoking status, sex, and percent emphysema. Results: Among 1,272 participants with COPD assessed for HAA, 424 were current smokers, and 249 were carriers of the variant MUC5B allele. A total of 519 participants were assessed for ILA. We found no association between pollution exposure and ILA or HAA. Associations between pollutant exposures and risk of ILA were modified by the presence of MUC5B polymorphism (P value interaction term for NOx = 0.04 and PM2.5 = 0.05) and smoking status (P value interaction term for NOx = 0.05; NO2 = 0.01; and ozone = 0.05). With higher exposure to NOx and PM2.5, MUC5B variant carriers had an increased risk of ILA (RR per 26 ppb NOx, 2.41; 95% confidence interval [CI], 0.97–6.0; and RR per 4 μg ⋅ m−3 PM2.5, 1.43; 95% CI, 0.93–2.2, respectively). With higher exposure to NO2, former smokers had an increased risk of ILA (RR per 10 ppb, 1.64; 95% CI, 1.0–2.7). Conclusions: Exposure to ambient air pollution was not associated with interstitial features on CT in this population of heavy smokers with COPD. MUC5B modified the association between pollution and ILA, suggesting that gene–environment interactions may influence prevalence of interstitial lung features in COPD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

Author

Radicioni, Giorgia, Ceppe, Agathe, Ford, Amina A, Alexis, Neil E, Barr, R Graham, Bleecker, Eugene R, Christenson, Stephanie A, Cooper, Christopher B, Han, MeiLan K, Hansel, Nadia N, Hastie, Annette T, Hoffman, Eric A, Kanner, Richard E, Martinez, Fernando J, Ozkan, Esin, Paine, Robert, III, Woodruff, Prescott G, O'Neal, Wanda K, Boucher, Richard C, and Kesimer, Mehmet

Published
2021
Full Text
View/download PDF

35. Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.

Author

Maddali, Manoj V., Moore, Andrew R., Sinha, Pratik, Newton, Chad A., Kim, John S., Adegunsoye, Ayodeji, Ma, Shwu-Fan, Strek, Mary E., Chen, Ching-Hsien, Linderholm, Angela L., Zemans, Rachel L., Moore, Bethany B., Wolters, Paul J., Martinez, Fernando J., Rogers, Angela J., Raj, Rishi, Noth, Imre, and Oldham, Justin M.

Subjects
IDIOPATHIC pulmonary fibrosis, TREATMENT effect heterogeneity, PULMONARY fibrosis, INDIVIDUALIZED medicine, PROTEIN domains
Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) causes irreversible fibrosis of the lung parenchyma. Although antifibrotic therapy can slow IPF progression, treatment response is variable. There exists a critical need to develop a precision medicine approach to IPF. Objectives: To identify and validate biologically driven molecular endotypes of IPF. Methods: Latent class analysis (LCA) was independently performed in prospectively recruited discovery (n = 875) and validation (n = 347) cohorts. Twenty-five plasma biomarkers associated with fibrogenesis served as class-defining variables. The association between molecular endotype and 4-year transplant-free survival was tested using multivariable Cox regression adjusted for baseline confounders. Endotype-dependent differential treatment response to future antifibrotic exposure was then assessed in a pooled cohort of patients naive to antifibrotic therapy at the time of biomarker measurement (n = 555). Measurements and Main Results: LCA independently identified two latent classes in both cohorts (P < 0.0001). WFDC2 (WAP four-disulfide core domain protein 2) was the most important determinant of class membership across cohorts. Membership in class 2 was characterized by higher biomarker concentrations and a higher risk of death or transplant (discovery, hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.64–2.48; P < 0.001; validation, HR, 1.95; 95% CI, 1.34–2.82; P < 0.001). In pooled analysis, significant heterogeneity in treatment effect was observed between endotypes (P = 0.030 for interaction), with a favorable antifibrotic response in class 2 (HR, 0.64; 95% CI, 0.45–0.93; P = 0.018) but not in class 1 (HR, 1.19; 95% CI, 0.77–1.84; P = 0.422). Conclusions: In this multicohort study, we identified two novel molecular endotypes of IPF with divergent clinical outcomes and responses to antifibrotic therapy. Pending further validation, these endotypes could enable a precision medicine approach for future IPF clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.

Author

Adegunsoye, Ayodeji, Kropski, Jonathan A., Behr, Juergen, Blackwell, Timothy S., Corte, Tamera J., Cottin, Vincent, Glanville, Allan R., Glassberg, Marilyn K., Griese, Matthias, Hunninghake, Gary M., Johannson, Kerri A., Keane, Michael P., Kim, John S., Kolb, Martin, Maher, Toby M., Oldham, Justin M., Podolanczuk, Anna J., Rosas, Ivan O., Martinez, Fernando J., and Noth, Imre

Subjects
GENETICS, INDIVIDUALIZED medicine, IDIOPATHIC pulmonary fibrosis, MOLECULAR shapes, INTERSTITIAL lung diseases, PULMONARY fibrosis
Abstract

Recent genetic and genomic advancements have elucidated the complex etiology of idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (ILDs), emphasizing the contribution of heritable factors. This state-of-the-art review synthesizes evidence on significant genetic contributors to pulmonary fibrosis (PF), including rare genetic variants and common SNPs. The MUC5B promoter variant is unusual, a common SNP that markedly elevates the risk of early and established PF. We address the utility of genetic variation in enhancing understanding of disease pathogenesis and clinical phenotypes, improving disease definitions, and informing prognosis and treatment response. Critical research gaps are highlighted, particularly the underrepresentation of non-European ancestries in PF genetic studies and the exploration of PF phenotypes beyond usual interstitial pneumonia/IPF. We discuss the role of telomere length, often critically short in PF, and its link to progression and mortality, underscoring the genetic complexity involving telomere biology genes (TERT, TERC) and others like SFTPC and MUC5B. In addition, we address the potential of gene-by-environment interactions to modulate disease manifestation, advocating for precision medicine in PF. Insights from gene expression profiling studies and multiomic analyses highlight the promise for understanding disease pathogenesis and offer new approaches to clinical care, therapeutic drug development, and biomarker discovery. Finally, we discuss the ethical, legal, and social implications of genomic research and therapies in PF, stressing the need for sound practices and informed clinical genetic discussions. Looking forward, we advocate for comprehensive genetic testing panels and polygenic risk scores to improve the management of PF and related ILDs across diverse populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis.

Author

Whalen, William, Berger, Kristin, Kim, John S., Simmons, Will, Ma, Shwu-Fan, Kaner, Robert J., Martinez, Fernando J., Anstrom, Kevin J., Parfrey, Helen, Maher, Toby M., Hammond, Matthew, Clark, Allan B., Thickett, David, Jenkins, R. Gisli, Wilson, Andrew M., and Noth, Imre

Subjects
TREATMENT effectiveness, PULMONARY fibrosis, SINGLE nucleotide polymorphisms, IDIOPATHIC pulmonary fibrosis, INSTITUTIONAL review boards
Abstract

The article discusses a study which identified a potential pharmacogenomic interaction between a single-nucleotide polymorphism (SNP) in Toll interactive protein (TOLLIP) and treatment with N-acetylceysteine in patients with idiopathic pulmonary fibrosis (IPF). Topics include TOLLIP SNPs associated with IPF susceptibility, how TOLLIP rs3750920 SNP genotyping was performed, and the need for further mechanistic studies to better understand the interplay between TOLLIP and doxycycline in IPF.

Published
2024
Full Text
View/download PDF

38. Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease.

Author

Huang, Yong, Ma, Shwu-Fan, Oldham, Justin M., Adegunsoye, Ayodeji, Zhu, Daisy, Murray, Susan, Kim, John S., Bonham, Catherine, Strickland, Emma, Linderholm, Angela L., Lee, Cathryn T., Paul, Tessy, Mannem, Hannah, Maher, Toby M., Molyneaux, Philip L., Strek, Mary E., Martinez, Fernando J., and Noth, Imre

Subjects
INTERSTITIAL lung diseases, MACHINE learning, IDIOPATHIC pulmonary fibrosis, RECEIVER operating characteristic curves, PROTEOMICS
Abstract

Rationale: Distinguishing connective tissue disease–associated interstitial lung disease (CTD-ILD) from idiopathic pulmonary fibrosis (IPF) can be clinically challenging. Objectives: To identify proteins that separate and classify patients with CTD-ILD and those with IPF. Methods: Four registries with 1,247 patients with IPF and 352 patients with CTD-ILD were included in analyses. Plasma samples were subjected to high-throughput proteomics assays. Protein features were prioritized using recursive feature elimination to construct a proteomic classifier. Multiple machine learning models, including support vector machine, LASSO (least absolute shrinkage and selection operator) regression, random forest, and imbalanced Random Forest, were trained and tested in independent cohorts. The validated models were used to classify each case iteratively in external datasets. Measurements and Main Results: A classifier with 37 proteins (proteomic classifier 37 [PC37]) was enriched in the biological process of bronchiole development and smooth muscle proliferation and immune responses. Four machine learning models used PC37 with sex and age score to generate continuous classification values. Receiver operating characteristic curve analyses of these scores demonstrated consistent areas under the curve of 0.85–0.90 in the test cohort and 0.94–0.96 in the single-sample dataset. Binary classification demonstrated 78.6–80.4% sensitivity and 76–84.4% specificity in the test cohort and 93.5–96.1% sensitivity and 69.5–77.6% specificity in the single-sample classification dataset. Composite analysis of all machine learning models confirmed 78.2% (194 of 248) accuracy in the test cohort and 82.9% (208 of 251) in the single-sample classification dataset. Conclusions: Multiple machine learning models trained with large cohort proteomic datasets consistently distinguished CTD-ILD from IPF. Many of the identified proteins are involved in immune pathways. We further developed a novel approach for single-sample classification, which could facilitate honing the differential diagnosis of ILD in challenging cases and improve clinical decision making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Vessel and Airway Characteristics in One-Year Computed Tomography–defined Rapid Emphysema Progression: SPIROMICS.

Author

Gerard, Sarah E., Dougherty, Timothy M., Nagpal, Prashant, Jin, Dakai, Han, MeiLan K., Newell Jr., John D., Saha, Punam K., Comellas, Alejandro P., Cooper, Christopher B., Couper, David, Fortis, Spyridon, Guo, Junfeng, Hansel, Nadia N., Kanner, Richard E., Kazeroni, Ella A., Martinez, Fernando J., Motahari, Amin, Paine III, Robert, Rennard, Stephen, and Schroeder, Joyce D.

Subjects
LUNGS, PULMONARY circulation, LUNG volume, CHRONIC obstructive pulmonary disease, OBSTRUCTIVE lung diseases, FORCED expiratory volume, VASCULAR resistance
Abstract

Rationale: Rates of emphysema progression vary in chronic obstructive pulmonary disease (COPD), and the relationships with vascular and airway pathophysiology remain unclear. Objectives: We sought to determine if indices of peripheral (segmental and beyond) pulmonary arterial dilation measured on computed tomography (CT) are associated with a 1-year index of emphysema (EI; percentage of voxels <−950 Hounsfield units) progression. Methods: Five hundred ninety-nine former and never-smokers (Global Initiative for Chronic Obstructive Lung Disease stages 0–3) were evaluated from the SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) cohort: rapid emphysema progressors (RPs; n = 188, 1-year ΔEI > 1%), nonprogressors (n = 301, 1-year ΔEI ± 0.5%), and never-smokers (n = 110). Segmental pulmonary arterial cross-sectional areas were standardized to associated airway luminal areas (segmental pulmonary artery–to–airway ratio [PAARseg]). Full-inspiratory CT scan–derived total (arteries and veins) pulmonary vascular volume (TPVV) was compared with small vessel volume (radius smaller than 0.75 mm). Ratios of airway to lung volume (an index of dysanapsis and COPD risk) were compared with ratios of TPVV to lung volume. Results: Compared with nonprogressors, RPs exhibited significantly larger PAARseg (0.73 ± 0.29 vs. 0.67 ± 0.23; P = 0.001), lower ratios of TPVV to lung volume (3.21 ± 0.42% vs. 3.48 ± 0.38%; P = 5.0 × 10−12), lower ratios of airway to lung volume (0.031 ± 0.003 vs. 0.034 ± 0.004; P = 6.1 × 10−13), and larger ratios of small vessel volume to TPVV (37.91 ± 4.26% vs. 35.53 ± 4.89%; P = 1.9 × 10−7). In adjusted analyses, an increment of 1 standard deviation in PAARseg was associated with a 98.4% higher rate of severe exacerbations (95% confidence interval, 29–206%; P = 0.002) and 79.3% higher odds of being in the RP group (95% confidence interval, 24–157%; P = 0.001). At 2-year follow-up, the CT-defined RP group demonstrated a significant decline in postbronchodilator percentage predicted forced expiratory volume in 1 second. Conclusions: Rapid one-year progression of emphysema was associated with indices indicative of higher peripheral pulmonary vascular resistance and a possible role played by pulmonary vascular–airway dysanapsis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis

Author

Leitao Filho, Fernando Sergio, Mattman, Andre, Schellenberg, Robert, Criner, Gerard J., Woodruff, Prescott, Lazarus, Stephen C., Albert, Richard K., Connett, John, Han, Meilan K., Gay, Steven E., Martinez, Fernando J., Fuhlbrigge, Anne L., Stoller, James K., MacIntyre, Neil R., Casaburi, Richard, Diaz, Philip, Panos, Ralph J., Cooper, J. Allen, Jr., Bailey, William C., LaFon, David C., Sciurba, Frank C., Kanner, Richard E., Yusen, Roger D., Au, David H., Pike, Kenneth C., Fan, Vincent S., Leung, Janice M., Man, Shu-Fan Paul, Aaron, Shawn D., Reed, Robert M., and Sin, Don D.

Published
2020
Full Text
View/download PDF

43. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial

Author

Keller, Thomas, Spece, Laura J., Donovan, Lucas M., Udris, Edmunds, Coggeshall, Scott S., Griffith, Matthew, Bryant, Alexander D., Casaburi, Richard, Cooper, J. Allen, Jr., Criner, Gerard J., Diaz, Philip T., Fuhlbrigge, Anne L., Gay, Steven E., Kanner, Richard E., Martinez, Fernando J., Panos, Ralph J., Shade, David, Sternberg, Alice, Stibolt, Thomas, Stoller, James K., Tonascia, James, Wise, Robert, Yusen, Roger D., Au, David H., and Feemster, Laura C.

Published
2020
Full Text
View/download PDF

45. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis

Author

Antoniou, Katerina M., Barber, Christopher M., Behr, Jürgen, Bonella, Francesco, Corte, Tamera, Costabel, Ulrich, Cottin, Vincent, Crestani, Bruno, Dalphin, Jean-Charles, Flaherty, Kevin R., Goh, Nicole, Johannson, Kerri A., Kondoh, Yasuhiro, Lederer, David, Lee, Joyce, Maher, Toby M., Martinez, Fernando J., Morell, Ferran, Noth, Imre, Raghu, Ganesh, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J., Ryu, Jay H., Salisbury, Margaret L., Singh, Sheetu, Selman, Moises, Strek, Mary E., Tarlo, Susan M., Tomassetti, Sara, Vancheri, Carlo, Vasakova, Martina, Wolters, Paul, Wells, Athol, Barnes, Hayley, Morisset, Julie, Molyneaux, Philip, Westall, Glen, Glaspole, Ian, and Collard, Harold R.

Published
2020
Full Text
View/download PDF

46. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort

Author

Alexis, Neil E., Anderson, Wayne H., Arjomandi, Mehrdad, Barjaktarevic, Igor, Barr, R. Graham, Bateman, Lori A., Bhatt, Surya P., Bleecker, Eugene R., Boucher, Richard C., Bowler, Russell P., Christenson, Stephanie A., Comellas, Alejandro P., Cooper, Christopher B., Couper, David J., Criner, Gerard J., Crystal, Ronald G., Curtis, Jeffrey L., Doerschuk, Claire M., Dransfield, Mark T., Drummond, Brad, Freeman, Christine M., Galban, Craig, Han, MeiLan K., Hansel, Nadia N., Hastie, Annette T., Hoffman, Eric A., Huang, Yvonne, Kaner, Robert J., Kanner, Richard E., Kleerup, Eric C., Krishnan, Jerry A., LaVange, Lisa M., Lazarus, Stephen C., Martinez, Fernando J., Meyers, Deborah A., Moore, Wendy C., Newell, John D., Jr., Paine, Robert, III, Paulin, Laura, Peters, Stephen P., Pirozzi, Cheryl, Putcha, Nirupama, Oelsner, Elizabeth C., O’Neal, Wanda K., Ortega, Victor E., Raman, Sanjeev, Rennard, Stephen I., Tashkin, Donald P., Wells, J. Michael, Wise, Robert A., Woodruff, Prescott G., Postow, Lisa, Viviano, Lisa, Burkes, Robert M., Ceppe, Agathe S., Couper, David, Cooper, Christopher, Labaki, Wassim W., Pirozzi, Cheryl S., Brown, Todd T., and Drummond, M. Bradley

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results